Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study - The Lancet Oncology
Saudi Arabia fleshes out its green targets during first day of SGI forum | Arab News